share_log

T2 Biosystems Regains Compliance With Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance With Nasdaq Continued Listing Requirements

T2 Biosystems恢复了对纳斯达克持续上市要求的合规性
T2 Biosystems ·  05/22 12:00

LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities ("MVLS") requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.

马萨诸塞州列克星敦,2024年5月22日(GLOBE NEWSWIRE)——快速检测败血症致病原体和抗生素耐药基因领域的领导者T2 Biosystems, Inc.(纳斯达克股票代码:TTOO)(“公司”)今天宣布,它已于2024年5月21日收到纳斯达克股票市场有限责任公司(“纳斯达克股票代码:TTOO”)(“公司”)的市值已恢复合规《纳斯达克上市规则》第5550(b)(2)(“规则”)中规定的上市证券(“MVLS”)要求继续在纳斯达克资本市场上市。

On November 22, 2023, the Company received written notice from Nasdaq informing the Company that Nasdaq had determined to delist the Company, as it was not in compliance with the Nasdaq's MVLS requirement because it failed to maintain a MVLS of at least $35 million for a period of 30 consecutive business days. On February 15, 2024, the Company appealed to the Nasdaq Hearings Panel for an exception to the MVLS requirement through May 20, 2024. On March 11, 2024, the Company received notice from the Nasdaq Hearings Panel that it had granted the Company an exception to the Nasdaq requirements, subject to the Company demonstrating compliance with the Rule on or before May 20, 2024.

2023年11月22日,公司收到纳斯达克的书面通知,通知该公司,纳斯达克决定将公司退市,因为纳斯达克没有遵守纳斯达克的MVLS要求,因为它未能在连续30个工作日内将MVLS维持在至少3500万美元的水平。2024年2月15日,该公司向纳斯达克听证小组提出上诉,要求在2024年5月20日之前豁免MVLS要求。2024年3月11日,公司收到纳斯达克听证小组的通知,称其已批准公司对纳斯达克要求的例外规定,前提是公司在2024年5月20日当天或之前证明遵守了该规则。

To regain compliance with the Rule, the Company was required to maintain a MVLS of at least $35 million for at least 10 consecutive trading days on or before May 20, 2024. This requirement was met on May 16, 2024, the tenth consecutive trading day when the MVLS was at least $35 million. The Company is currently in full compliance with NASDAQ continued listing requirements.

为了恢复对该规则的遵守,公司必须在2024年5月20日当天或之前至少连续10个交易日将MVLS维持在至少3500万澳元的水平。这一要求在2024年5月16日得到满足,这是连续第十个交易日MVLS至少为3500万美元。该公司目前完全遵守纳斯达克的持续上市要求。

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. For more information, please visit www.t2biosystems.com.

关于 T2 生物系统
T2 Biosystems是快速检测诱发败血症的病原体和抗生素耐药基因领域的领导者,致力于通过帮助临床医生比以往任何时候都更快地有效治疗患者来改善患者护理和降低护理成本。T2 Biosystems 的产品包括 T2Dx 仪器,T2Bertia 小组,T2Candida 面板,T2Restance 面板和 T2Biothreat Panel,由专有的 T2 磁共振 (T2MR) 提供动力) 技术。T2 Biosystems 拥有活跃的未来产品线,包括美国的 T2Resistance 小组、 耳念珠菌 测试,以及 T2Lyme 小组。欲了解更多信息,请访问 www.t2biosystems.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements about the Company's ability to maintain compliance with the listing requirements of the Nasdaq Capital Market, including its ability to effect a reverse share split, as well as statements that include the words "expect," "intend," "plan", "believe", "project", "forecast", "estimate," "may," "should," "anticipate," and similar statements of a future or forward looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) ability to continue as a going concern, or (v) the factors discussed under Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, or SEC, on April 1, 2024, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company's silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.

前瞻性陈述
本新闻稿包含1995年《私人证券诉讼改革法》所指的前瞻性陈述。本新闻稿中包含的所有与历史事实无关的陈述均应被视为前瞻性陈述,包括但不限于关于公司遵守纳斯达克资本市场上市要求的能力(包括其进行反向股票拆分的能力)的陈述,以及包含 “预期”、“打算”、“计划”、“相信”、“项目”、“预测”、“估计”、“可能” 等字样的陈述” “应该”、“预测” 以及具有未来或前瞻性质的类似陈述。这些前瞻性陈述基于管理层当前的预期。这些陈述既不是承诺也不是保证,但涉及已知和未知的风险、不确定性和其他重要因素,这些因素可能导致实际结果、业绩或成就与前瞻性陈述所表达或暗示的任何未来业绩、业绩或成就存在重大差异,包括但不限于:(i) 无法 (a) 实现承诺、合同或产品的预期收益;(b) 成功执行战略优先事项;(c) 将产品推向市场;(d) 扩大产品的使用或采用率;(e) 获取客户证言;(f) 准确预测增长假设;(g) 实现预期收入;(h) 产生预期的运营支出水平;或 (i) 增加客户设施的高风险患者人数;(ii) 早期数据无法预测最终结果;(iii) 未能在预期的时间范围内或根本没有提交或获得预期的美国食品药品管理局申请或许可;或 (iv) 继续经营的能力,或 (v) 项目1A下讨论的因素。公司于2024年4月1日向美国证券交易委员会(SEC)提交的截至2023年12月31日年度的10-K表年度报告以及公司不时向美国证券交易委员会提交的其他文件中的 “风险因素”。这些和其他重要因素可能导致实际业绩与本新闻稿中前瞻性陈述所示的结果存在重大差异。任何此类前瞻性陈述均代表管理层截至本新闻稿发布之日的估计。尽管除非法律要求,否则公司可能会选择在未来的某个时候更新此类前瞻性陈述,但它不承担任何更新此类前瞻性陈述的义务,即使随后发生的事件导致其观点发生变化。因此,任何人都不应假设公司随着时间的推移保持沉默意味着实际事件如此类前瞻性陈述中所明示或暗示的那样得到证实。不应将这些前瞻性陈述视为本新闻稿发布之日后任何日期的公司观点。

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406

投资者联系人:
菲利普·特里普泰勒,吉尔马丁集团
philip@gilmartinIR.com 415-937-5406

Primary Logo

Source: T2 Biosystems, Inc.

来源:T2 Biosystems, Inc.

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发